Artificial Intelligence
Pleurodynia Treatment Market Size Will Attain USD 191.58 Million by 2030 Growing at 5.28% CAGR – Exclusive Report by Zion Market Research | Global Pleurodynia Treatment Market Size, Share, Trends Analysis Report
<!– Name:DistributionId Value:8811247 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2791 –> <!– Name:CustomerId Value:1092386 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:7d300dc1-0797-43e3-bfdb-5a07d7329ac1 –>
Dublin, Ireland, April 19, 2023 (GLOBE NEWSWIRE) — Zion Market Research has published a new research report titled “Pleurodynia Treatment Market By Causes (Coxsackievirus B, Coxsackievirus A, And Echovirus), By Complications (Meningitis, Tachycardia, Hepatitis, Pericarditis, Myocarditis, And Orchitis)), By Symptoms (Chest Pain, Cough, Fever, Sore Throat, Headache, And Muscular Aches & Pains), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030” in its research database.
“According to the latest research study, the demand of global Pleurodynia Treatment Market size & share was valued at approximately USD 128.57 million in 2022. The market is expected to grow above a CAGR of 5.28% and is anticipated to reach over USD 191.58 million by 2030.”
The report analyses the pleurodynia treatment market’s drivers and restraints, as well as the impact they have on-demand throughout the projection period. In addition, the report examines global opportunities in the global market.
Pleurodynia Treatment Market Overview:
The pleurodynia treatment industry revolves around the production and use of drugs, therapies, and other treatment options that are used to manage the symptoms of pleurodynia which is also known as Bornholm disease. The condition is characterized by symptoms like fever, severe chest & abdominal pain, and muscle stiffness. It is caused by enteroviruses, such as Echovirus and Coxsackievirus B. Studies have shown that pleurodynia is self-restricted which means that it will cure on its own after some time.
Get a Free Sample PDF of this Research Report for more Insights – https://www.zionmarketresearch.com/sample/pleurodynia-treatment-market
(Before you plan to buy, sample reports are a great option to examine our in-depth studies or reports)
However, cases with severe symptoms require additional medical care. Currently, the healthcare sector does not have any accurate cure for the condition since there are no US Food & Drugs Administration (FDA)-approved drugs for the treatment. However, several antiviral drugs and other therapies may be used to manage the symptoms of the condition. The industry revolves around companies and organizations involved in the development, production, and distribution of these treatments along with healthcare professionals.
Our Free Sample Report Consists of the Following:
- Introduction, Overview, and in-depth industry analysis are all included in the 2023 updated report.
- About 199+ Pages Research Report (Including Recent Research)
- Provide detailed chapter-by-chapter guidance on Request
- Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2023
- Includes Tables and figures have been updated
- The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, Revenue Analysis, SWOT Analysis, Historic and Forecast Growth, Porter’s 5 Forces Analysis
- Zion Market Research Methodology
Report Scope:
| Report Attributes | Report Details |
| Report Name | Pleurodynia Treatment Market Research Report |
| Market Size in 2022 | USD 128.57 Million |
| Market Forecast in 2030 | USD 191.58 Million |
| Growth Rate | CAGR of 5.28% |
| Number of Pages | 199 |
| Key Companies Covered | Roche Holding AG, Gilead Sciences, AbbVie, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Boehringer Ingelheim, Pfizer, Novartis, Takeda Pharmaceuticals, Merck & Co., Bayer, Teva Pharmaceutical Industries, AstraZeneca, Amgen, Eli Lilly and Company, Sanofi, Daiichi Sankyo, and Astellas Pharma. |
| Segments Covered | By Causes, By Complications, By Symptoms, And By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
| Base Year | 2022 |
| Historical Year | 2016 to 2020 |
| Forecast Year | 2023 – 2030 |
| Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Key Insights from Primary Research
- As per the analysis, the pleurodynia treatment market share is likely to grow above a CAGR of around 5.28% between 2023 and 2030.
- The Pleurodynia Treatment market size was worth around US$ 128.57 million in 2022 and is estimated to hit approximately US$ 191.58 million by 2030. Due to a variety of driving factors, the market is predicted to rise at a significant rate.
- The pleurodynia treatment market is projected to grow at a significant rate due to the growing prevalence of the condition
- Based on symptoms segmentation, chest pain was predicted to show maximum market share in the year 2022
- Based on causes segmentation, Coxsackievirus B was the leading cause in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Directly Purchase a Copy of the Report | Quick Delivery Available – https://www.zionmarketresearch.com/buynow/su/pleurodynia-treatment-market
Industry Dynamics:
Growth Drivers
- Growing prevalence of the condition to propel market growth
The global pleurodynia treatment market is projected to grow owing to increasing awareness about the condition. The industry is relatively new and the symptoms of pleurodynia can be easily associated with other conditions since the symptoms are very common. However, the growing number of cases has led to the government and healthcare industry undertaking several initiatives targeting the generation of mass awareness related to the condition and the treatment methods that can be used. Furthermore, the healthcare sector is also investing in various research activities to understand the virus and develop novel drugs and therapies that can provide accurate care.
The pleurodynia treatment industry may also benefit from the overall growing investments in healthcare infrastructure witnessed across the globe. Countries are investing in deploying more effective treatment solutions due to increased pressure caused by growing expectations and demand from patients for adequate care. In addition to this, advances in technology are expected to drive the development of new treatments for pleurodynia. For instance, the use of artificial intelligence and machine learning could help to identify new drug targets and develop more effective treatments.
To know more about this report | Request A Free Sample Copy
Restraints
- Availability of only limited treatment options
One of the key drawbacks in the industry is the availability of only limited treatment options. Currently, there are no remedies for treating the condition from its root. The medicines available in the pleurodynia treatment market only assist in managing the associated symptoms or pain relief. The patient may have to deal with the condition on their own and wait for it to subside in case of an absolute lack of access to medical care. This is further affected by the lack of adequate awareness amongst the population and healthcare professionals, especially in emerging economies.
Opportunities & Challenges
The growing investment toward novel therapies may prove growth opportunities while the regulatory challenges could restrict market expansion.
Pleurodynia Treatment Market: Segmentation Analysis
The global pleurodynia treatment market is segmented based on causes, complications, symptoms, and region.
Based on causes, the global market segments are Coxsackievirus B, Coxsackievirus A, and echovirus. In 2022, the industry witnessed the highest growth in the Coxsackievirus B segment since it is considered the largest cause of the condition. Various studies have indicated that more than 90% of the cases of pleurodynia are caused by Coxsackievirus B while the rest of the two reasons remain relatively low in terms of leading cause. The virus is a member of the enterovirus family and exists alongside Coxsackievirus A and Echovirus. It can be easily transmitted through close contact with an infected patient or from contaminated food or water, and surfaces. The infected patient may suffer from various symptoms including fever, headache, muscle aches, and respiratory concerns.
Based on complications, the pleurodynia treatment industry divisions are meningitis, tachycardia, hepatitis, pericarditis, myocarditis, and orchitis. In 2022, the industry witnessed the highest growth in the pericarditis and myocarditis segments. The former refers to the inflammation of the heart-surrounding sac whereas the latter is the inflammation of the heart muscle itself. The complications include symptoms like chest pain and heart failure and can be serious if not handled with precaution. The rest of the complications like meningitis, tachycardia, hepatitis, and orchitis are not very common but it is important to note that every patient’s case history is different from the rest.
Based on symptoms, the global market divisions are chest pain, cough, fever, sore throat, headache, and muscular aches & pain.
Browse Complete Report Here | Pleurodynia Treatment Market By Causes, By Complications, By Symptoms, and By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030
Regional Analysis:
- North America to lead with the highest growth rate
North America is anticipated to lead the global pleurodynia treatment market due to the high incidence rate of the condition and the presence of well-established healthcare infrastructure. In addition to this, the increasing investment in R&D activities and the presence of major pharmaceutical companies in the region are expected to drive regional market growth. Europe is also expected to be a significant market for pleurodynia treatment due to the increasing prevalence of the condition in the region.
The presence of favorable government policies and reimbursement schemes, as well as the increasing investment in healthcare infrastructure. Growth in Asia-Pacific may be driven due to the presence of a large patient pool, increasing healthcare spending, and the rising adoption of advanced healthcare technologies.
Competitive Players:
The report contains qualitative and quantitative research on the global pleurodynia treatment market, as well as detailed insights and development strategies employed by the leading competitors.
Some of the main players in the global pleurodynia treatment market include;
- Roche Holding AG
- Gilead Sciences
- AbbVie
- GlaxoSmithKline
- Bristol Myers Squibb
- Johnson & Johnson
- Boehringer Ingelheim
- Pfizer
- Novartis
- Takeda Pharmaceuticals
- Merck & Co.
- Bayer
- Teva Pharmaceutical Industries
Request for Customization on this Report as per your requirements – https://www.zionmarketresearch.com/custom/7149
(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)
Recent Industry Developments:
- In January 2023, verywellhealth, an online award-winning site that provides fact-based and credible information on various aspects of health-related conditions, claimed that although there is no specific treatment for the condition, patients can use nonsteroidal anti-inflammatory drugs like ibuprofen (Advil) to reduce pleurodynia-related pain. They also suggested that the application of warm packs on the affected area may also help relieve pain
- In April 2022, a study published on the Frontiers site claimed that ethyl 3-hydroxy hexanoate (EHX) which is a volatile compound found in food additives and fruits can be a potential compound working against Coxsackievirus B infections. The study also suggested that the use of EHX can be considered a safe therapeutic option during the treatment process
The global pleurodynia treatment market is segmented as follows:
By Causes
- Coxsackievirus B
- Coxsackievirus A
- Echovirus
By Complications
- Meningitis
- Tachycardia
- Hepatitis
- Pericarditis
- Myocarditis
- Orchitis
By Symptoms
- Chest Pain
- Cough
- Fever
- Sore Throat
- Headache
- Muscular Aches & Pains
By Region
- North America
- The U.S.
- Canada
- Europe
- France
- The UK
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Southeast Asia
- The Middle East & Africa
- GCC
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Have Any Query? Ask Our Experts: https://www.zionmarketresearch.com/inquiry/pleurodynia-treatment-market
Key questions answered in this report:
- What is the size of the pleurodynia treatment market and what is its expected growth rate?
- What are the primary driving factors that push the pleurodynia treatment market forward?
- What are the pleurodynia treatment Industry’s top companies?
- What are the different categories that the pleurodynia treatment Market caters to?
- What will be the fastest-growing segment or region?
- In the value chain, what role do essential players play?
- What is the procedure for getting a free copy of the pleurodynia treatment market sample report and company profiles?
Key Offerings:
- Market Size, Trends, & Forecast by Revenue | 2023−2030
- Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
- Market Segmentation – A detailed analysis by Causes, Complications, Symptoms, and Region
- Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Browse Other Related Research Reports from Zion Market Research
About Zion Market Research:
Zion Market Research is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Zion Market Research are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.
Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Rushikesh Dorge
USA: +1 347 690-0211 | UK: +44 2032 894158 | Japan: +81 50 5806 9039 | India: +91 7768 006 007
Email: [email protected] | Web: https://www.zionmarketresearch.com/
Follow Us on – LinkedIn | Twitter | Facebook | Pinterest | YouTube
Read Our Blogs: https://zmrblog.com/
LONDON, May 1, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT; CLVT PR A) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the “Preferred Shares”), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price (“VWAP”) of Clarivate’s ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the “valuation period”). If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share. The mandatory conversion rate will be announced following the end of the valuation period. The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the “Statement of Rights” for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate’s annual report on Form 10-K for the fiscal year ended December 31, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clarivate-declares-dividend-on-mandatory-convertible-preferred-shares-302133633.html
BEIJING, May 1, 2024 /PRNewswire/ — Focusing on the development of AI, the third CMG Forum was held on Monday in Beijing.
Li Shulei, a member of the Political Bureau of the Communist Party of China (CPC) Central Committee and the head of the Publicity Department of the CPC Central Committee, attended the opening of the event and delivered a speech.
Guests at the forum stressed the role of media in promoting the innovative application of AI as well as its governance.
Efforts should also be made to boost the development of AI in creating positive, healthy, diverse and high-quality content, so that AI can become a force for good and benefit mankind, they agreed.
They also called on media to accelerate intelligent transformation and help bridge international exchanges and cooperation on the governance of AI to facilitate its healthy, orderly and safe development.
Hosted by China Media Group (CMG), the forum attracted more than 200 participants from international organizations, media, think tanks and multinational companies.
“Innovation and breakthroughs in science and technology not only guide the development and progress of human civilization, but also bring uncertainty to the changing world,” said Shen Haixiong, vice minister of the Publicity Department of the CPC Central Committee and president of CMG. He called for efforts to jointly create valuable and responsible artificial intelligence.
AI technology is affecting every aspect of our lives. Thomas Bach, president of the International Olympic Committee (IOC), stated in a video speech that CMG has always been a partner of the IOC, bringing the charm of the Olympic Games to hundreds of millions of Chinese viewers. He said the IOC invites CMG to work together for the creation of a future with the application of AI in Olympic sports.
“From ancient inventions such as silk, printing and the compass to modern technological advances such as robotics, telecommunications and green technology, China has always been committed to innovation and creation,” said Daren Tang, director general of the World Intellectual Property Organization (WIPO). He said WIPO pays close attention to ensuring a balance between the opportunities and risks of artificial intelligence and is committed to strengthening cooperation to ensure that artificial intelligence is properly used.
https://news.cgtn.com/news/2024-04-30/3rd-CMG-Forum-in-Beijing-discusses-AI-development-1tdDcXvCexG/p.html
View original content:https://www.prnewswire.co.uk/news-releases/cgtn-3rd-cmg-forum-in-beijing-discusses-ai-development-302133410.html
Artificial Intelligence
Trianz Appoints Sridhar Kannan as Practice Leader – Digital, Elevating its Leadership in the Global Digital Transformation Space
SANTA CLARA, Calif., May 1, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Sridhar Kannan as Practice Leader – Digital. With over 25 years of extensive experience in technology and business leadership, Sridhar joins Trianz to lead the expansion of Trianz’s Digital Practice, forging strategic alliances and expanding the business footprint.
Sridhar’s appointment comes at a transformative phase for Trianz as it solidifies its commitment to redefining the digital landscape with an “IP Led” model. This strategic shift is powered by Trianz’s cutting-edge hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace. Sridhar’s visionary leadership in technology-led business transformations across diverse sectors will be instrumental in leveraging IP-led models and innovative methodologies to position Trianz at the forefront of digital transformation.
“We are thrilled to welcome Sridhar Kannan to the Trianz family,” said Seshi Vanguru, Chief Revenue Officer at Trianz. “His appointment marks a significant stride in Trianz’s journey toward innovation and excellence. Sridhar’s wealth of experience and exceptional leadership skills will elevate our Digital Practice to new heights, reaffirming our commitment to delivering exceptional value to our clients.”
Sridhar is recognized as a client-focused technology and business transformation executive with a remarkable track record of helping Banking and Financial Services organizations in business transformation and product innovation using applications, cloud, data, and digital solutions. His extensive prior experience at industry giants such as Wipro, Cognizant, and Infosys include successfully leading Fortune 10 global client relationships and implementing transformative solutions across Banking, Financial Services, and Healthcare industries. Sridhar is highly regarded for his ability to lead global cross-functional teams, foster collaboration, and achieve aggressive business goals while consistently delivering high levels of client satisfaction.
“I am deeply honored to join Trianz and contribute to its mission of shaping the future through digital transformation,” said Sridhar. “Together, we will push the boundaries of what’s possible and drive meaningful impact for our clients in this rapidly evolving digital landscape.”
Based out of Minnesota, US, Sridhar has steered numerous clients towards success through the strategic application of Digital, Cloud, Product Engineering, Data, AI, and Application services, making him a seasoned strategist in today’s dynamic digital landscape. His appointment marks a significant milestone in Trianz’s journey to nurturing talent and delivering world-class solutions.
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our “IP Led Transformations” approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media Team : [email protected]+1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/trianz-appoints-sridhar-kannan-as-practice-leader–digital-elevating-its-leadership-in-the-global-digital-transformation-space-302132835.html
-
Uncategorized7 days agoCherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence6 days agoHikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days agoHITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence6 days agoWeb O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Artificial Intelligence6 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence5 days agoCognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Uncategorized6 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry
